KR102950333B1 - 레보케토코나졸로 질환을 치료하는 방법 - Google Patents

레보케토코나졸로 질환을 치료하는 방법

Info

Publication number
KR102950333B1
KR102950333B1 KR1020217031645A KR20217031645A KR102950333B1 KR 102950333 B1 KR102950333 B1 KR 102950333B1 KR 1020217031645 A KR1020217031645 A KR 1020217031645A KR 20217031645 A KR20217031645 A KR 20217031645A KR 102950333 B1 KR102950333 B1 KR 102950333B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
subject
pharmaceutically acceptable
acceptable salt
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217031645A
Other languages
English (en)
Korean (ko)
Other versions
KR20210135278A (ko
Inventor
프레드릭 코헨
Original Assignee
스트롱브릿지 더블린 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102950333(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 스트롱브릿지 더블린 리미티드 filed Critical 스트롱브릿지 더블린 리미티드
Priority to KR1020267010641A priority Critical patent/KR20260049881A/ko
Publication of KR20210135278A publication Critical patent/KR20210135278A/ko
Application granted granted Critical
Publication of KR102950333B1 publication Critical patent/KR102950333B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020217031645A 2019-03-04 2020-03-02 레보케토코나졸로 질환을 치료하는 방법 Active KR102950333B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267010641A KR20260049881A (ko) 2019-03-04 2020-03-02 레보케토코나졸로 질환을 치료하는 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813399P 2019-03-04 2019-03-04
US62/813,399 2019-03-04
PCT/US2020/020644 WO2020180784A1 (en) 2019-03-04 2020-03-02 Methods of treating disease with levoketoconazole

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267010641A Division KR20260049881A (ko) 2019-03-04 2020-03-02 레보케토코나졸로 질환을 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20210135278A KR20210135278A (ko) 2021-11-12
KR102950333B1 true KR102950333B1 (ko) 2026-04-08

Family

ID=72338256

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217031645A Active KR102950333B1 (ko) 2019-03-04 2020-03-02 레보케토코나졸로 질환을 치료하는 방법
KR1020267010641A Pending KR20260049881A (ko) 2019-03-04 2020-03-02 레보케토코나졸로 질환을 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267010641A Pending KR20260049881A (ko) 2019-03-04 2020-03-02 레보케토코나졸로 질환을 치료하는 방법

Country Status (10)

Country Link
US (5) US11020393B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934649A4 (cg-RX-API-DMAC7.html)
JP (3) JP7574204B2 (cg-RX-API-DMAC7.html)
KR (2) KR102950333B1 (cg-RX-API-DMAC7.html)
CN (1) CN113710250A (cg-RX-API-DMAC7.html)
AU (2) AU2020232246B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017561A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132319A1 (cg-RX-API-DMAC7.html)
IL (2) IL330346A (cg-RX-API-DMAC7.html)
WO (1) WO2020180784A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3934649A4 (en) * 2019-03-04 2022-11-23 Strongbridge Dublin Limited METHODS OF TREATMENT OF DISEASES WITH LEVOKETOCONAZOLE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072881A1 (en) * 2005-01-10 2006-07-13 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009116632A (ru) * 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
US9522432B2 (en) * 2012-06-01 2016-12-20 Herbert W. Staub Cradle cutter
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US10512667B2 (en) * 2017-06-27 2019-12-24 The Regents Of The University Of Michigan Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
EP3934649A4 (en) * 2019-03-04 2022-11-23 Strongbridge Dublin Limited METHODS OF TREATMENT OF DISEASES WITH LEVOKETOCONAZOLE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072881A1 (en) * 2005-01-10 2006-07-13 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Also Published As

Publication number Publication date
JP7801408B2 (ja) 2026-01-16
US11278547B2 (en) 2022-03-22
IL286099A (en) 2021-10-31
AU2020232246A1 (en) 2021-10-07
US20210267970A1 (en) 2021-09-02
US20250387389A1 (en) 2025-12-25
JP2022522873A (ja) 2022-04-20
EP3934649A1 (en) 2022-01-12
AU2020232246B2 (en) 2025-03-20
US20240148724A1 (en) 2024-05-09
WO2020180784A1 (en) 2020-09-10
EP3934649A4 (en) 2022-11-23
JP7574204B2 (ja) 2024-10-28
US11903940B2 (en) 2024-02-20
KR20210135278A (ko) 2021-11-12
JP2026082828A (ja) 2026-05-19
CA3132319A1 (en) 2020-09-10
AU2025204382A1 (en) 2025-07-03
US12377096B2 (en) 2025-08-05
KR20260049881A (ko) 2026-04-14
JP2025026838A (ja) 2025-02-26
US11020393B2 (en) 2021-06-01
IL330346A (en) 2026-08-01
US20220387425A1 (en) 2022-12-08
BR112021017561A2 (pt) 2021-11-09
US20200397781A1 (en) 2020-12-24
CN113710250A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
CN107249591B (zh) 固体药物配制品及其制备方法
JP2023515817A (ja) ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN110022900A (zh) 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
US11925619B2 (en) Treatments with nirogacestat
EP2720696A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
US20240261378A1 (en) Trim proteins and galectins cooperate and codirect autophagy and are useful in the treatment of autophagy related diseases
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
JP2026082828A (ja) レボケトコナゾールによる疾患の処置方法
HK40062461A (en) Methods of treating disease with levoketoconazole
US20240180874A1 (en) Improved treatment of ovarian cancer with nirogacestat
CA3215383A1 (en) Pharmaceutical composition, and preparation method therefor and application thereof
TW201607535A (zh) 無類固醇之疾病管理

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)